Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 14, 2004

View Archived Issues

Simultaneous targeting of tumor proliferation and angiogenesis shows promising results in vivo

Erbitux in phase III for NSCLC

Interim results of BrachySil phase IIa study in liver cancer patients

Yondelis receives orphan drug status for soft tissue sarcoma

Peninsula completes phase I study for PPI-0903

Cand5 enters phase I study for AMD

BDC-03 under development for cachexia

Positive phase II results for cetrorelix in BPH

Diamyd studied in type 2 diabetes patients in Sweden

Phase III Inactine acute study cleared to continue

Celltech researchers claim anti-IL-1beta antibodies and their use

Novel gastric antisecretory agents discovered at Altana

New NO-releasing COX inhibitors in early development at Altana

New MIF inhibitors prepared and tested at Avanir

AstraZeneca team presents new P2X7 antagonists

Aventis scientists design inhibitors of fungal CIV1 and other kinases

Three novel series of pyridine-based immunosuppressants developed at AstraZeneca

No FDA approval for Exanta

Norditropin NordiFlex receives FDA approval

In vivo tumor growth inhibition and apoptosis induced by human agonistic TRAIL receptor 2 antibody

Novel prophylactic and therapeutic HPV vaccine approach

Antibody therapy promising against C. difficile

Progress in development and testing of recombinant hookworm vaccine

Orally active cathepsin K inhibitor prevents bone loss in vitro and in vivo

ArTec prepares to review preclinical application for Tubercin with FDA

Allergan and Peplin discontinue PEP-005 collaboration

Neoprobe updates RIGScan CR and Lymphoseek programs

Initiation of MERLIN TIMI-36 study of Ranexa

Provecta IND cleared

Nabi begins a new clinical trial with PhosLo in ESRD

Ursodeoxycholate boosts chemoprotective efficacy of sulindac

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...